AstraZeneca 1Q Core Earnings Per Share Misses Estimate

AstraZeneca Plc said first-quarter earnings fell 12 percent as its best-selling treatments faced generic competition and costs rose following acquisitions. Earnings per share excluding one-time items declined to 95 cents, the London-based company said Friday in a statement. Analysts had predicted 96 cents a share, according to the average of estimates compiled by Bloomberg. Bloomberg's Sam Fazeli reports on "Countdown" with Anna Edwards.

Full Show: What'd You Miss? (08/22)
07:00 - Guests include: Miller Tabak's Matt Maley and Temple University's Alexandra Guisinger. (Source: Bloomberg)
  • Full Show: Bloomberg Technology (08/22)
  • SAP's Russell Sees Strong Growth in India, Japan
  • The Key Takeaways From Salesforce's Earnings